Novel pulmonary vascular imaging signs in COVID-19: pathophysiology, significance and management.

A growing body of evidence points to the frequent involvement of pulmonary microvessels in COVID-19 which was recognized first on CT, and subsequently demonstrated by clinical and pathological studies. Microvasculopathy occurring chiefly from endothelial and pericyte damage with resultant disruption of immune, thrombotic and renin-angiotensin-aldosterone balance leads to a constellation of clinical and biochemical derangements. Exploration of potential therapies directed at normalizing the vascular health can prove a major boon in the treatment of COVID-19.